
News|Articles|January 1, 2006
First-time generic approvals
Hydromorphone tablets 2, 4, and 8 mg (equiv to Dilaudid tablets)
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
3
7 takeaways from the MHE webinar on PBM reform and transparency
4
Prior authorization isn’t shrinking. Its savings are
5





















